Quincy Attobrah

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Monjuvi and Revlimid plus R-CHOP helped patients with high-risk diffuse large B-cell lymphoma stay in remission longer and reduce relapse risk.

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

Keytruda plus Lynparza showed clinical activity but missed its primary efficacy goal in BRCA-mutated metastatic pancreatic cancer.

Teen cancer survivor Brynn and friend Teddy created Soothe Note, a free app helping patients track symptoms and prepare for appointments.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses.

FDA approves Imfinzi plus BCG for adults with high-risk non-muscle invasive bladder cancer based on phase 3 POTOMAC trial results.

A healthy, active 39-year-old shares how blood in his urine led to a bladder cancer diagnosis and becoming first in Texas to receive Inlexzo.

ASCO 2026 will feature new gynecologic cancer research, including advances in immunotherapy, ADCs, vaccines and targeted therapies.

After losing his mother to colorectal cancer, Colorectal Cancer Alliance CEO Michael Sapienza turned grief into advocacy to improve screening, treatment and patient care.

Colonoscopies can do more than detect colorectal cancer early — they can prevent it by removing precancerous polyps before cancer develops.

Zynyz plus chemotherapy improved overall survival for patients with advanced anal cancer in the phase 3 POD1UM-303/InterAACT-2 trial.

New research suggests gut bacteria may play a role in fatigue and pain experienced by melanoma patients receiving immunotherapy.

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in cancer survivors.

After a devastating pancreatic cancer diagnosis, Sharon chose a personalized treatment path that helped inspire future research.

The FDA approved Bizengri for NRG1+ cholangiocarcinoma, offering a new option for patients with this rare, advanced bile duct cancer.

Multiple myeloma death rates are declining as targeted therapies and immunotherapy improve survival, offering patients longer lives and more treatment options.

Elrexfio improved progression-free survival in multiple myeloma, helping patients live longer without disease worsening in a phase 3 trial.

Colorectal cancer is rising in younger adults. Dr. Jeremy Kortmansky, discusses causes, symptoms, screening barriers, and prevention.

FDA reviews Ziihera combinations for HER2-positive gastroesophageal cancer, showing potential benefit as a first-line treatment option for patients.

The National Ovarian Cancer Coalition (NOCC) delivers free meals to ovarian cancer patients, easing treatment burdens and supporting caregivers nationwide.

Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.

Treatment with Verzenio and letrozole may help control advanced or recurrent endometrial cancer for some patients, according to new research.

Diabetes drug metformin may mimic exercise effects in prostate cancer, supporting weight, metabolism and overall health during treatment.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating development for patients with few options.

Cogent submitted an FDA application for bezuclastinib after the phase 3 PEAK trial shows improved progression-free survival in patients with previously treated GIST.

The phase 3 EMERALD-3 trial shows Imfinzi and Imjudo plus Lenvima and embolization improved progression-free survival in unresectable liver cancer.